Literature DB >> 23648827

Urological cancer: walking the tightrope of survival and quality of life with ADT.

Matthew J Resnick1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23648827     DOI： 10.1038/nrclinonc.2013.78

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.

Authors:  Geoffrey R Norman; Jeff A Sloan; Kathleen W Wyrwich
Journal:  Med Care       Date:  2003-05       Impact factor: 2.983

2.  Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.

Authors:  Shabbir M H Alibhai; Henriette Breunis; Narhari Timilshina; Calvin Johnston; George Tomlinson; Ian Tannock; Murray Krahn; Neil E Fleshner; Padraig Warde; Sarah Duff Canning; Lawrence Klotz; Gary Naglie
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

3.  Measurement of health status. Ascertaining the minimal clinically important difference.

Authors:  R Jaeschke; J Singer; G H Guyatt
Journal:  Control Clin Trials       Date:  1989-12

4.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

Authors:  E F Juniper; G H Guyatt; A Willan; L E Griffith
Journal:  J Clin Epidemiol       Date:  1994-01       Impact factor: 6.437

5.  Intermittent androgen suppression for rising PSA level after radiotherapy.

Authors:  Juanita M Crook; Christopher J O'Callaghan; Graeme Duncan; David P Dearnaley; Celestia S Higano; Eric M Horwitz; Eliot Frymire; Shawn Malone; Joseph Chin; Abdenour Nabid; Padraig Warde; Thomas Corbett; Steve Angyalfi; S Larry Goldenberg; Mary K Gospodarowicz; Fred Saad; John P Logue; Emma Hall; Paul F Schellhammer; Keyue Ding; Laurence Klotz
Journal:  N Engl J Med       Date:  2012-09-06       Impact factor: 91.245

6.  Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry.

Authors:  Natalia Sadetsky; Kirsten Greene; Matthew R Cooperberg; Alan Hubbard; Peter R Carroll; William Satariano
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

7.  Minimum important difference between patients with rheumatoid arthritis: the patient's perspective.

Authors:  G A Wells; P Tugwell; G R Kraag; P R Baker; J Groh; D A Redelmeier
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

8.  Intermittent versus continuous androgen deprivation in prostate cancer.

Authors:  Maha Hussain; Catherine M Tangen; Donna L Berry; Celestia S Higano; E David Crawford; Glenn Liu; George Wilding; Stephen Prescott; Subramanian Kanaga Sundaram; Eric Jay Small; Nancy Ann Dawson; Bryan J Donnelly; Peter M Venner; Ulka N Vaishampayan; Paul F Schellhammer; David I Quinn; Derek Raghavan; Benjamin Ely; Carol M Moinpour; Nicholas J Vogelzang; Ian M Thompson
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

9.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Authors:  Fernando E C Calais da Silva; Aldo V Bono; Peter Whelan; Maurizio Brausi; Anton Marques Queimadelos; Jose A Portillo Martin; Ziya Kirkali; Fernando M V Calais da Silva; Chris Robertson
Journal:  Eur Urol       Date:  2009-02-21       Impact factor: 20.096
  9 in total
  1 in total

1.  Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.

Authors:  Maha Hussain; Catherine Tangen; Celestia Higano; Nicholas Vogelzang; Ian Thompson
Journal:  J Clin Oncol       Date:  2015-11-09       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.